These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31766977)

  • 1. Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Randomized Clinical Trial.
    Marian MJ; Abu Daya H; Chatterjee A; Al Solaiman F; Sasse MF; Fonbah WS; Workman RW; Johnson BE; Carlson SE; Brott BC; Prabhu SD; Leesar MA
    J Am Heart Assoc; 2019 Dec; 8(23):e012844. PubMed ID: 31766977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.
    Marian MJ; Alli O; Al Solaiman F; Brott BC; Sasse M; Leesar T; Prabhu SD; Leesar MA
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28611098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
    Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome.
    Zhang YR; Xue ZK; Chen KY; Xu LX; Wang WD; Tao HY; Liu T; Che JJ; Wang XW; Rha SW; Wang JR; Wang P
    Perfusion; 2021 Mar; 36(2):122-129. PubMed ID: 32522095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study).
    Liu GZ; Zhang S; Sun DH; Shi J; Bo WL; Wang WN; Zhang CY; Wang ZH; Feng W; He MJ; Liu YY; Li S; Zheng LQ; Li Y
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1059-1068. PubMed ID: 31081522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
    Gurbel PA; Bliden KP; Saucedo JF; Suarez TA; DiChiara J; Antonino MJ; Mahla E; Singla A; Herzog WR; Bassi AK; Hennebry TA; Gesheff TB; Tantry US
    J Am Coll Cardiol; 2009 Feb; 53(8):648-57. PubMed ID: 19232896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
    O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
    Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin withdrawal in patients treated with ticagrelor presenting with non-ST elevation myocardial infarction.
    Beigel R; Mazin I; Koifman E; Shechter M; Pres H; Shlomo N; Rosenberg N; Asher E; Matetzky S
    J Thromb Haemost; 2018 Apr; 16(4):663-669. PubMed ID: 29443445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
    Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
    Caiazzo G; De Rosa S; Torella D; Spaccarotella C; Mongiardo A; Giampà S; Micieli M; Palella E; Gulletta E; Indolfi C
    Circ Cardiovasc Interv; 2014 Feb; 7(1):104-12. PubMed ID: 24449597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Laine M; Panagides V; Frère C; Cuisset T; Gouarne C; Jouve B; Thuny F; Paganelli F; Alessi MC; Mancini J; Bonello L
    J Thromb Haemost; 2019 Dec; 17(12):2188-2195. PubMed ID: 31351022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.
    Piqueras-Flores J; Jurado-Román A; López-Lluva MT; Sánchez-Pérez I; Abellán-Huerta J; Lozano-Ruiz Poveda F
    J Cardiovasc Pharmacol; 2019 Jan; 73(1):56-59. PubMed ID: 30383607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches.
    Xue Y; Hu Z; Jing Y; Wu H; Li X; Wang J; Seybert A; Xie X; Lv Q
    J Clin Pharm Ther; 2020 Oct; 45(5):1076-1086. PubMed ID: 32627223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS).
    Musallam A; Orvin K; Perl L; Mosseri M; Arbel Y; Roguin A; Lev EI
    Can J Cardiol; 2016 Oct; 32(10):1246.e13-1246.e19. PubMed ID: 26971236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
    Khan JN; Greenwood JP; Nazir SA; Lai FY; Dalby M; Curzen N; Hetherington S; Kelly DJ; Blackman D; Peebles C; Wong J; Flather M; Swanton H; Gershlick AH; McCann GP
    J Am Heart Assoc; 2016 May; 5(6):. PubMed ID: 27247336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.
    Wang C; Zheng W; Shaqdan A; Wang C; Qin X; Zhao X; Wang X; Yuan L; Nie S; Liu R
    Platelets; 2020; 31(3):337-343. PubMed ID: 31043110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.